Laurus Labs Ltd. IPO subscribed 4.54 times on the Final ​ Day till 07:00 PM​

Mumbai, December 8, 2016: The maiden initial public offering (“IPO”) of Laurus Labs Limited, was subscribed overall by 4.54 times on the final day (December 8, 2016) of the IPO.

Commenting on the overwhelming response on the IPO, Dr. Satyanarayana Chava, Founder Promoter & CEO, Laurus Labs Ltd. said, “We take this opportunity to thank all the investors who have shown trust in our business and helped make our maiden IPO a successful one. I assure them of keeping their trust in us justified in the future as well.”

For your reference please find appended below the subscription details as of 07:00 pm:-

Laurus Labs Ltd  IPO Subscription Update - 6 Dec 2016 to 8 Dec 2016
IPO Subscription Update - Final Day @  7pm
Category	Shares	Total Bids	Subscription	Demand (INR Cr)
QIB	6,174,544	65,061,465	10.54x	2,784.6
HNI	4,623,879	16,545,060	3.58x	708.1
Retail	10,789,051	17,414,565	1.61x	745.3
Employees	323,834	551,775	1.70x	21.4
Total	21,911,308	99,572,865	4.54x	4,259.5

Laurus Labs Ltd. - IPO Update
Opens	Tuesday, December 6 , 2016
Closes	Thursday, December 8 , 2016
Price Band	INR 426 to INR  428
Fresh issue	Up to INR 300 crore
Offer For Sale	24,107,440 shares or INR 1031.79 crore at upper price band
Total Issue Size	INR 1331.79 crore at upper price band
Bid Lot	35  Equity Shares
Allocation	QIB 50%, HNI 15% & Retail 35%

About Laurus Labs Limited:

Laurus Labs Limited (“Laurus Labs”) is a leading research and development (“R&D”) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (“APIs”) for select, high-growth therapeutic areas of anti-retrovirals (“ARVs”) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas. Their strategic and early investments in R&D and manufacturing infrastructure have enabled them to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing “donor-funded access-to-medicines markets” of Sub-Saharan Africa, South-East Asia and Latin America. During the financial year 2016, Laurus Labs sold APIs in 32 countries.  Laurus Labs also has a growing synthesis and nutraceutical/cosmeceutical ingredients businesses. Further, they are increasingly focused towards growing their integrated generics finished dosage forms (“FDFs”) business in which they have made significant investments over the last two financial years. Laurus Labs operates in four business lines: Generics – APIs, Generics – FDFs, Synthesis and Ingredients.

Tweet

Subscribe to receive free email updates: